Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
iShares Biotechnology ETF
(NASDAQ:IBB)
Intraday
$128.05
0.29
[0.23%]
After-Hours
$128.05
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$128.05
0.29
[0.23%]
At close: Apr 24
$128.05
0
[0.00%]
PreMarket: 8:43AM EDT
Get Report
Watch
Overview
News
Dividends
Short Interest
Latest News for iShares Biotechnology ETF (NASDAQ:IBB)
iShares Biotechnology ETF (NASDAQ: IBB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, January 29, 2024
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
Neil Dennis
-
Jan 29, 2024, 9:02AM
Friday, January 05, 2024
Live On CNBC, Jason Snipe's Contrarian Idea: Biotech; Names IShares Biotechnology ETF
Benzinga Newsdesk
-
Jan 5, 2024, 12:42PM
Wednesday, January 03, 2024
US Stocks Eye 3-Day Slump; Tech, Crypto Sell-Off Deepens, Oil, Dollar Rebound: What's Driving Markets Wednesday?
Piero Cingari
-
Jan 3, 2024, 1:23PM
Tuesday, January 02, 2024
Tech Drags On Wall Street As 2024 Kicks Off; Dollar and Treasury Yields Surge: What's Driving Markets Tuesday?
Piero Cingari
-
Jan 2, 2024, 1:29PM
Friday, December 29, 2023
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
Surbhi Jain
-
Dec 29, 2023, 8:34AM
Tuesday, December 26, 2023
Wall Street Sees Post-Holiday Gains, Oil Rallies, Intel Leads: What's Driving Markets Tuesday?
Piero Cingari
-
Dec 26, 2023, 12:47PM
Friday, December 22, 2023
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
Piero Cingari
-
Dec 22, 2023, 1:04PM
Thursday, December 21, 2023
US Stocks Bounce; Chipmakers, Cruise Lines Lead, Dollar Falls: What's Driving Markets Thursday?
Piero Cingari
-
Dec 21, 2023, 2:11PM
Wednesday, December 20, 2023
Wall Street Edges Higher, Small Caps Eye Best Month In 3 Years, Bitcoin Rebounds: What's Driving Markets Wednesday?
Piero Cingari
-
Dec 20, 2023, 1:47PM
Tuesday, November 07, 2023
Activist Investor Elliott Pushes for Strategy Revamp at BioMarin Amid CEO Change
Vandana Singh
-
Nov 7, 2023, 4:12PM
Thursday, August 31, 2023
Industry ETFs In The Spotlight: August's Winners And Losers Revealed: Where Is Gold, Energy And Biotech?
Piero Cingari
-
Aug 31, 2023, 12:48PM
Saturday, August 12, 2023
Weight-Loss Drug Wegovy Adds Mass To Novo Nordisk's stock, Pushing Valuation Past Denmark's GDP
Shanthi Rexaline
-
Aug 12, 2023, 3:31PM
Thursday, August 10, 2023
Disinflation Talk Grows, Rate Hike Bets Plummet: Top 5 ETFs Rallying On CPI Miss
Piero Cingari
-
Aug 10, 2023, 11:58AM
Monday, July 31, 2023
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers
Piero Cingari
-
Jul 31, 2023, 10:59AM
Thursday, April 13, 2023
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
Vandana Singh
-
Apr 13, 2023, 2:54PM
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
Vandana Singh
-
Apr 13, 2023, 7:38AM
Wednesday, April 12, 2023
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
Vandana Singh
-
Apr 12, 2023, 9:46AM
Tuesday, April 11, 2023
Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead
Vandana Singh
-
Apr 11, 2023, 2:28PM
Thursday, April 06, 2023
FDA Withdraws Lone Premature Birth Drug Makena Over Lack of Proven Benefits
Vandana Singh
-
Apr 6, 2023, 1:45PM
AbbVie, Thermo Fisher Scientific And A Must-Watch Biotech ETF: CNBC's 'Final Trades'
Lisa Levin
-
Apr 6, 2023, 8:49AM
Thursday, March 16, 2023
US Judge Weighs Nationwide Ban On Abortion Pills
Vandana Singh
-
Mar 16, 2023, 8:56AM
Monday, March 13, 2023
Silicon Valley Bank Meltdown Hits Healthcare Sector As Well
Vandana Singh
-
Mar 13, 2023, 8:05AM
Friday, March 10, 2023
Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs
Vandana Singh
-
Mar 10, 2023, 1:10PM
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Vandana Singh
-
Mar 10, 2023, 11:46AM
Wednesday, March 08, 2023
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Vandana Singh
-
Mar 8, 2023, 5:21AM
Tuesday, March 07, 2023
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Vandana Singh
-
Mar 7, 2023, 7:34PM
Wednesday, March 01, 2023
FDA Takes Action To Restrict Unlawful Import Of Animal Tranquilizer 'Tranq' Or ''Zombie Drug'
Vandana Singh
-
Mar 1, 2023, 1:24PM
Monday, February 20, 2023
Man in Germany Cured of HIV After Undergoing Stem Cell Transplant, According to Report in Nature Medicine
Charles Gross
-
Feb 20, 2023, 1:14PM
Tuesday, January 31, 2023
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Shanthi Rexaline
-
Jan 31, 2023, 2:33PM
Friday, January 06, 2023
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Benzinga Newsdesk
-
Jan 6, 2023, 3:17PM
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
Benzinga Newsdesk
-
Jan 6, 2023, 2:47PM
Tuesday, December 27, 2022
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Shanthi Rexaline
-
Dec 27, 2022, 9:11AM
Monday, December 05, 2022
Meta Platforms, This Biotech ETF And These China Plays Are CNBC's 'Final Trades'
Priya Nigam
-
Dec 5, 2022, 8:23AM
Friday, December 02, 2022
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
Shanthi Rexaline
-
Dec 2, 2022, 6:01AM
Thursday, December 01, 2022
BriaCell's Lead Candidate Bria-IMT™ Shows Promising Results For Advanced Breast Cancer Patients
Faith Ashmore
-
Sponsored
Tuesday, November 01, 2022
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
-
Nov 1, 2022, 4:01PM
Thursday, October 27, 2022
These 4 ETFs Feature on CNBC's 'Final Trades'
Priya Nigam
-
Oct 27, 2022, 8:58AM
Sunday, October 02, 2022
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
-
Oct 2, 2022, 9:49AM
Wednesday, August 31, 2022
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Shanthi Rexaline
-
Aug 31, 2022, 2:52PM
Wednesday, August 10, 2022
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Vandana Singh
-
Aug 10, 2022, 11:33AM
Tuesday, August 09, 2022
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Vandana Singh
-
Aug 9, 2022, 9:08AM
Friday, August 05, 2022
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
Vandana Singh
-
Aug 5, 2022, 11:35AM
Thursday, August 04, 2022
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Vandana Singh
-
Aug 4, 2022, 9:06AM
Wednesday, August 03, 2022
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Vandana Singh
-
Aug 3, 2022, 10:13AM
Tuesday, August 02, 2022
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Vandana Singh
-
Aug 2, 2022, 8:27AM
Monday, August 01, 2022
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Vandana Singh
-
Aug 1, 2022, 9:03AM
Sunday, July 31, 2022
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Shanthi Rexaline
-
Jul 31, 2022, 9:21AM
Friday, July 29, 2022
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Vandana Singh
-
Jul 29, 2022, 10:27AM
Thursday, July 28, 2022
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Vandana Singh
-
Jul 28, 2022, 10:37AM
Wednesday, July 27, 2022
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Vandana Singh
-
Jul 27, 2022, 9:28AM
Show more
